Study of In‐Vitro Release Characteristics of Carbamazepine Extended Release Semisolid Matrix Filled Capsules Based on Gelucires

References

• Giunchedi P., Conte U., La Manna A. Carbamazepine modified release dosage forms. Drug Dev. Ind. Pharm. 1991; 17: 1753–1764
   Web of Science ®Google Scholar
• Larkin J. G., Mecllelan A., Munday A., Sutherland M., Bulter E., Brodie M. J. A double blind comparison of conventional and controlled release formulations of carbamazepine in healthy subjects. Br. J. Clin. Pharm. 1989; 27: 313–322
   PubMed Web of Science ®Google Scholar
• Giunchedi P., Maggi L., Conte U., La Manna A. Linear extended release of a water insoluble drug, carbamazepine, from erodible matrix. Int. J. Pharm. 1993; 94: 15–22, [CROSSREF]
   Web of Science ®Google Scholar
• Stevens R. E., Limsakun T., Evans G., Mason D. H., Jr. Controlled multidose pharmacokinetic evaluation of two extended release carbamazepine formulations (Carbatrol and Tegretol‐XR). J. Pharm. Sci. 1998; 87: 1531–1534, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• The Tegretol OROS Osmotic release delivery system study group, double‐blind crossover comparison of Tegretol‐XR and Tegretol in patients with epilepsy. Neurology 1995; 45: 1703–1707, [CSA]
   PubMed Web of Science ®Google Scholar
• Walters P. A., Rowley G., Pearson J. T., Taytor C. J. Formulation and physical properties of thixotropic gels for hard gelatin capsules. Drug Dev. Ind. Pharm. 1992; 18: 1613–1631
   Web of Science ®Google Scholar
• Baykara T., Yuksel N. The preparation of prolonged action formulations in the form of semi‐solid matrix into hard gelatin capsules of oxprenolol. II Thixocap method. Drug Dev. Ind. Pharm. 1992; 18: 233–243
   Web of Science ®Google Scholar
• Duclos R., Bourret E., Brossard C. Rheology of polyol behenates and drug release from matrix monolithic capsules. Int. J. Pharm. 1999; 182: 145–154, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Bodmeier R., Paeratakul O., Chen H., Zhang W. Formation of sustained release wax matrices within hard gelatin capsules in fluidized bed. Drug Dev. Ind. Pharm. 1990; 16: 1505–1519
   Web of Science ®Google Scholar
• Vial‐Bernasconi A. C., Buri P., Doelker E., Beyssac E., Duchaix G., Aiache J. M. In vivo evaluation of an indomethacin monolithic, extended zero‐order release hard gelatin capsule formulation based on saturated polyglycolyzed glycerides. Pharm. Acta Helv. 1995; 70: 307–313, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Brossard C., Ratsimbazafy V., Lefort des Ylouses D. Modelling of theophylline compound release from hard gelatin capsules containing Gelucire matrix granules. Drug Dev. Ind. Pharm. 1991; 17: 1262–1277
   Google Scholar
• Ratsimbazafy V., Bourret E., Duclos R., Brossard C. Rheological behavior of drug suspensions in Gelucire mixtures and proxyphylline release from matrix hard gelatin capsules. Eur. J. Pharm. Biopharm. 1999; 48: 247–252, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Buri P., Vial‐Bernasconi A. C., Doelker E. Modulation de la cinetique et de la vitesse de liberation par un choix adequat de l'excipient: exemple des Gelucires. Bull. Tech. Gattefosse 1985; 78: 67–73, [CSA]
   Google Scholar
• Remunan C., Bretal M. J., Nunez A., Jato J. L.V. Accelerated stability study of sustained‐release nifedipine tablets prepared with Gelucire. Int. J. Pharm. 1992; 80: 151–159, [CROSSREF]
   Web of Science ®Google Scholar
• Damian F., Blaton N., Kinget R., Van‐den‐Mooter G. Physical stability of solid dispersions of the antiviral agent UC‐781 with PEG6000, Gelucire 44/14 and PVP K30. Int. J. Pharm. 2002; 244: 87–98, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• San‐Vicente A., Hernandez R. M., Gascon M. B., Pedraz J. L. Effect of aging on the release of salbutamol sulfate from lipid matrices. Int. J. Pharm. 2000; 208: 13–21, [CROSSREF]
   PubMedGoogle Scholar
• Sutananta W., Craig D. Q.M., Newton J. M. Investigation into the effects of preparation conditions and storage on the rate of drug release from pharmaceutical glyceride bases. J. Pharm. Phamacol. 1995; 47: 355–359
   PubMed Web of Science ®Google Scholar
• Laine E., Auramo P., Kahela P. On the structural behaviour of triglycerides with time. Int. J. Pharm. 1988; 43: 241–247, [CROSSREF]
   Web of Science ®Google Scholar
• EL‐Massik M. A., Abdallah O. Y., Galal S., Daabis N. A. Development of a Dissolution Medium for Carbamazepine. Paper presented at the Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA 2000
   Google Scholar
• Peppas N. A. Analysis of fickian and non fickian drug release from polymers. Pharm. Acta Helv. 1985; 60: 110–111, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Peppas N. A., Sahlin J. J. A simple equation for the description of solute release III. Coupling of diffusion and relaxation. Int. J. Pharm. 1989; 57: 169–172, [CROSSREF]
   Web of Science ®Google Scholar
• Bamba M., Puisieux F., Marty J. P., Carstensen J. T. Release mechanisms in gel forming sustained release preparations. Int. J. Pharm. 1979; 2: 307–315, [CROSSREF]
   Web of Science ®Google Scholar
• Prapaitrakul W., Sprockel O. L. Shivanand. Release of chlorpheniramine maleate from fatty acid ester matrix disks prepared by melt‐extrusion. J. Pharm. Pharmacol. 1991; 43: 337–381
   PubMedGoogle Scholar
• Doelker C., Doelker E., Buri P., Waginaire L. The incorporation and in‐vitro release profiles of liquid, deliquescent or unstable drugs with fusible excipients in hard gelatin capsules. Drug Dev. Ind. Pharm. 1986; 12: 1553–1565
   Web of Science ®Google Scholar
• Sutananta W., Craig D. Q.M., Newton J. M. Evaluation of the mechanism of drug release from glyceride bases. J. Pharm. Pharmacol. 1995; 47: 182–187, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Franz R. M., Sytsma J. A., Smith B. P., Lucisano L. J. In vitro evaluation of a mixed polymeric sustained‐release matrix using response surface methodology. J. Control. Release 1987; 5: 159–172, [CROSSREF]
   Google Scholar
• Baykara T., Yuksel N. The preparation of prolonged action formulations in the form of semi‐solid matrix into hard gelatin capsules of oxprenolol. I Thermocap method. Drug Dev. Ind. Pharm. 1991; 17: 1215–1227
   Web of Science ®Google Scholar
• Naidoo N. T. Encapsulation and in vitro release of indomethacin from semi‐solid matrix capsules. Int. J. Pharm. 1989; 55: 53–57, [CROSSREF]
   Web of Science ®Google Scholar
• Dah Z. M., Realdon N., Ragazzi E., Dalla F. G. Effects of two different kinds of silicon dioxide on release of drugs from suppositories: benzydamine hydrochloride. Farmaco 1991; 46: 699–711
   PubMedGoogle Scholar
• Sutananta W., Craig D. Q.M., Newton J. M. The effects of ageing on the thermal behaviour and mechanical properties of pharmaceutical glycerides. Int. J. Pharm. 1994; 111: 51–62, [CROSSREF]
   Web of Science ®Google Scholar
• Duddu S. P., Roussin P., Laforet J. P., Palepu N. R. Effect of physical structure of Gelucire 50/13 on the release of theophylline from a Gelucire 50/13‐theophylline formulation. Bull Tech. Gattefosse 1996; No 89: 53–59
   Google Scholar
• El Massik M. A., Abdallah O. Y., Galal S., Daabis N. A. Semisolid matrix filled capsules: An approach to improve dissolution stability of phenytoin sodium formulation. Drug Dev. Ind. Pharm. 2003; 29: 531–543, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar